The global metagenomic sequencing market size was valued at USD 2582.8 million in 2025 and is projected to grow from USD 3034.79 million in 2026 to USD 11026.35 million by 2034, registering a CAGR of 17.5% during the forecast period from 2026 to 2034. North America dominated the metagenomic sequencing market with a market share of 42.5% in 2025.
Metagenomics is a biological approach in genomics that analyzes mixed genomic materials derived from a community of organisms using metagenomic sequencing. This approach gives detailed information on species diversity and abundance, functional genes, evolutionary relationships, population structure, and environmental factor correlation networks. Although these processes were developed for clinical diagnostics, drug discovery, biofuel, and industrial applications, they are now being employed for other purposes. Metagenomics allows researchers to study creatures difficult to culture in the lab because most microbes have never been cultured.
Download a Free Sample To learn more about this report,
Real-Time Nanopore Metagenomics Moving Closer to Clinical Decision-Making
Conventional culture-based diagnostics can take several days to identify bloodstream pathogens and resistance patterns, limiting the speed of targeted antimicrobial treatment. Real-time nanopore sequencing is therefore moving clinical metagenomics toward faster pathogen identification; a 2026 study of 307 positive blood cultures achieved 97.7% agreement with conventional species identification, while 93.7% of correctly identified organisms were detected within the first hour of sequencing. The result is a more clinically relevant Metagenomic Sequencing Market where rapid sequencing, pathogen detection, and infectious disease diagnostics can support earlier treatment decisions.
Metagenomic Sequencing Expanding into Antimicrobial Resistance Surveillance
Traditional antimicrobial resistance surveillance often depends on cultured isolates, which can limit visibility across complex microbial communities and emerging resistance genes. Metagenomic sequencing is therefore becoming part of broader genomic surveillance strategies; the U.S. CDC’s FY2026 budget request included USD 66 million for Advanced Molecular Detection, including a proposed Biothreat Radar capability for multi-pathogen metagenomic surveillance, while WHO’s global AMR surveillance system analyzed more than 23 million confirmed infection cases in its latest reporting cycle. The result is a broader Metagenomic Sequencing Market where resistome profiling, genomic surveillance, and One Health monitoring strengthen detection of antimicrobial resistance across clinical and public-health environments.
Unexplained Infectious Disease Cases Supporting Diagnostic Demand and Cloud Bioinformatics Infrastructure Supporting Data Analysis Capacity Drive Market
Unexplained infectious disease cases create demand for metagenomic sequencing because conventional targeted tests may fail when the causative organism is uncommon, unexpected, or previously unidentified. A 2025 CDC report noted that approximately 50% of encephalitis cases worldwide remain undiagnosed by conventional testing, highlighting a substantial diagnostic gap. Another 2025 CDC study detected pathogenic respiratory viruses in 17 of 52 SARS-CoV-2-negative samples through metagenomic sequencing. This demand-side transition supports wider use of metagenomic sequencing for difficult infectious disease investigations and broad pathogen identification.
Cloud bioinformatics infrastructure strengthens market supply by providing scalable computing, storage, and analytical resources needed to process large metagenomic sequencing datasets. The NIH Strategic Plan for Data Science 2025–2030 reported more than 200 petabytes of biomedical data hosted in the cloud and around 5,000 researchers trained through its cloud initiatives. NIH cloud platforms also support genomic datasets covering more than 3.2 million research participants in dbGaP and over 500,000 participants in the All of Us program. This supply-side capacity lowers dependence on local computing infrastructure and supports broader access to metagenomic analysis across research and public-health laboratories.
Regulatory and Clinical Validation Challenges and Contamination and Background DNA Interference Restrain Market Expansion
Clinical metagenomic sequencing requires strong evidence for analytical sensitivity, specificity, reproducibility, bioinformatics performance, and result interpretation before routine diagnostic use. In September 2026, the FDA identified analytical validation, data interpretation, and integration into existing safety-testing frameworks as continuing implementation challenges for NGS-based detection methods. These validation requirements increase development time and testing costs, slowing broader clinical adoption of metagenomic sequencing.
Metagenomic sequencing can detect DNA from reagents, laboratory environments, host cells, and other background sources, making it difficult to distinguish genuine microbial signals from contamination. A 2025 clinical study of 623 tissue samples reported that 60 samples, or 9.6%, were uninterpretable because of quality-control failures or suspected contamination, illustrating the practical impact on diagnostic workflows. Additional negative controls, sequencing depth, filtering, and confirmatory testing raise costs and can reduce confidence in results, limiting wider Metagenomic Sequencing Market adoption.
Expansion of Microbiome-Based Drug Discovery and Therapeutic Development and Growth of Metagenomic Sequencing in Agricultural Soil and Plant Health Analysis Offers Growth Opportunities
Biotechnology companies, pharmaceutical developers, microbiome research firms, and contract research organizations represent the main commercial groups for this opportunity. NIH continues to support microbiome-based therapeutic research, including precision probiotic programs with phased research periods of up to 5 years, reflecting sustained institutional investment in translating microbiome science into treatments. Metagenomic sequencing providers can create revenue through biomarker discovery, microbial target identification, patient stratification, sequencing services, and therapeutic research partnerships.Agricultural biotechnology companies, seed developers, crop-protection firms, agronomy laboratories, and precision agriculture providers form the key customer base for this opportunity. USDA awarded USD 7.1 million to nine agricultural microbiome research projects in 2026, while its research programs use genome-resolved metagenomics to study microbes linked with crop resilience and soil health. Metagenomic service providers can create revenue through soil microbiome profiling, crop-health diagnostics, microbial screening, agronomic advisory packages, and long-term field-monitoring programs.
High Computational Burden from Large Sequencing Data Volumes and Fragmented Bioinformatics Pipelines Complicate Result Interpretation Hinders Growth
Metagenomic sequencing providers must process millions of sequencing reads per clinical sample, creating substantial requirements for computing, storage, and bioinformatics capacity. A 2025 CDC metagenomic sequencing study generated a median of 5.8 million reads per sample before applying a three-stage bioinformatics workflow for pathogen identification. Such data volumes increase processing workloads and turnaround complexity, making high-throughput metagenomic services harder to scale efficiently.
Metagenomic sequencing companies must manage multiple classification algorithms, reference databases, file formats, and analytical pipelines, which can produce differences in organism identification and reporting. CDC notes that clinical genomic workflows use both commercial pipelines and numerous open-source tools, requiring laboratories to maintain comparability and reproducibility across analytical environments. This fragmentation increases workflow-management and computational-validation workloads, making standardized large-scale deployment more difficult.
The reagents and consumables segment dominated the metagenomic sequencing market with a market share of 54.6% in 2025, supported by their recurring use across sample preparation, library construction, amplification, purification, and sequencing workflows. Every sequencing run requires multiple consumable inputs, creating a continuous replacement cycle across research laboratories, diagnostic facilities, and genomics centers.
The services segment is expected to register the fastest CAGR of 19.3% during the forecast period 2026–2034, supported by organizations outsourcing sequencing, bioinformatics, data interpretation, and specialized metagenomic analysis instead of maintaining full in-house infrastructure. Instruments remain essential for core sequencing operations where laboratories require direct control over throughput, workflow design, and sample processing.
Request Customizationto receive a tailored report.
The shotgun metagenomic sequencing segment dominated the metagenomic sequencing market with a market share of 41.7% in 2025, reflecting its ability to analyze total genetic material within complex samples without limiting detection to specific microbial groups. This approach supports broad microbial profiling, functional analysis, and identification of organisms that may be missed by targeted sequencing methods.
The metatranscriptomic segment is expected to grow at the fastest CAGR of 20.2% during the forecast period 2026–2034, supported by its ability to examine actively expressed genes and reveal how microbial communities function under specific biological or environmental conditions. 16S rRNA sequencing remains widely used for bacterial community profiling, while whole genome sequencing and de novo assembly provide deeper genomic characterization where organism-level resolution is required.
The drug discovery segment dominated the metagenomic sequencing market with a market share of 30.8% in 2025, supported by the use of microbial genomic data to identify novel enzymes, metabolites, therapeutic targets, and biologically active compounds from complex microbial communities. Metagenomic datasets also help researchers study host-microbiome interactions that may influence disease pathways and treatment response.
The clinical diagnostics segment is expected to register the fastest CAGR of 20.4% during the forecast period 2026–2034, supported by the ability of sequencing-based approaches to detect multiple pathogens from a single sample when conventional tests provide limited answers. Ecological and environmental metagenomics supports biodiversity and microbial ecosystem studies, biofuel applications explore microorganisms and enzymes involved in biomass conversion, while industrial applications use microbial information to optimize bioprocessing and biotechnology workflows.
Speak to an Analystto discuss market opportunities.
The North America metagenomic sequencing market accounted for the largest regional share of 42.5% in 2025. Regional leadership reflects advanced genomic research infrastructure, broad use of next-generation sequencing, substantial microbiome research activity, and integration of metagenomic methods across clinical, environmental, and public-health applications.
The U.S. metagenomic sequencing market is influenced by a proposed USD 66 million allocation for Advanced Molecular Detection in FY2027, an increase of USD 23 million from FY2026. Funding is intended to expand multi-pathogen metagenomic surveillance, sequencing analytics, cloud computing, and state and local laboratory capabilities.
The Canada metagenomic sequencing market is shaped by CAD 175.1 million in genomics funding over seven years starting in 2024–25. Investment across healthcare, pandemic preparedness, agriculture, biosecurity, and environmental research is broadening the use of high-throughput sequencing and genomic analysis.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific metagenomic sequencing market is expected to register the fastest CAGR of 20.6% during the forecast period 2026–2034. Regional expansion is driven by greater genomic research capacity, wider sequencing infrastructure, and expanding applications across infectious-disease surveillance, precision medicine, biotechnology, and environmental monitoring.
The Japan metagenomic sequencing market is influenced by plans to conduct whole-genome analysis for about 15,000 cancer cases in FY2026. Continued development of genomic and multi-omics data infrastructure is strengthening sequencing applications in diagnosis, personalized medicine, and drug discovery.
The China metagenomic sequencing market is shaped by plans to establish a rapid multi-point infectious-disease surveillance system by 2030. Provincial and eligible municipal disease-control institutions are expected to develop capabilities in high-throughput multi-pathogen testing, metagenomic sequencing, and bioinformatics analysis.
The India metagenomic sequencing market is influenced by a long-term goal to sequence one million genomes and a national bioeconomy projected to reach USD 300 billion by 2030. Expansion of genomic datasets and bioinformatics capacity creates a broader research environment for advanced sequencing applications.
The Europe metagenomic sequencing market is shaped by established genomics programs, collaborative research networks, and greater use of sequencing-based approaches in public health and life-science research. Continued development of bioinformatics capabilities and coordinated pathogen-surveillance programs is strengthening metagenomic adoption.
The U.K. metagenomic sequencing market is influenced by a five-year Pathogen Genomics Strategy that expands nationally coordinated sequencing for emerging infections, antimicrobial resistance, and vaccine surveillance. Inclusion of newer metagenomic technologies broadens their role in routine pathogen detection and public-health monitoring.
The Germany metagenomic sequencing market is shaped by the Global Health Protection Programme Phase 3, which will run from 2026 to 2028 with around EUR 22 million across 19 projects. Priorities in genomic sequencing, laboratory diagnostics, surveillance, and One Health capacity development create additional applications for metagenomic analysis.
The metagenomic sequencing market is moderately consolidated, with sequencing technology companies, genomic service providers, bioinformatics firms, and research-focused life science companies serving microbiome analysis, infectious disease research, environmental genomomics, and clinical applications. Leading players include BGI Genomics Co., Ltd., Oxford Nanopore Technologies Ltd., Eurofins Genomics, Illumina, Inc., and Macrogen Inc., which together are estimated to account for approximately 40–45% of the global metagenomic sequencing market share.
Established players compete through sequencing accuracy, platform throughput, bioinformatics capabilities, and broad research customer networks. Emerging and regional players within the metagenomic sequencing market ecosystem compete through specialized analytical services, flexible sequencing workflows, competitive pricing, and localized support for academic, clinical, and environmental research projects.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Antibody Purification Service Market Size, Forecast, Demand, Opportunities, 2034
Red Biotechnology Market Size, Share, Growth, Forecast, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Cell Line Development Services Market Size, Share, 2034
Base Editing Market Size, Share, Growth, Analysis, Report, 2034
Gene Therapy Cell Culture Media Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com